DK2528617T3 - Interleukin-2 eller interferon-alpha til anvendelse ved behandling af nikotin- eller spisehang - Google Patents

Interleukin-2 eller interferon-alpha til anvendelse ved behandling af nikotin- eller spisehang Download PDF

Info

Publication number
DK2528617T3
DK2528617T3 DK11705472.6T DK11705472T DK2528617T3 DK 2528617 T3 DK2528617 T3 DK 2528617T3 DK 11705472 T DK11705472 T DK 11705472T DK 2528617 T3 DK2528617 T3 DK 2528617T3
Authority
DK
Denmark
Prior art keywords
cytokine
interleukin
administration
nicotine
cytokines
Prior art date
Application number
DK11705472.6T
Other languages
English (en)
Inventor
Edith Huland
Original Assignee
Immunservice Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunservice Gmbh filed Critical Immunservice Gmbh
Application granted granted Critical
Publication of DK2528617T3 publication Critical patent/DK2528617T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Claims (9)

1. Cytokin til anvendelse ved behandling af en hang, hvor hangen er nikotinhang eller spisehang og hvor cytokinet er interleukin-2 eller interferon-alpha.
2. Cytokin til anvendelse ifølge krav 1, hvor nikotinhangen er til et tobaksprodukt.
3. Cytokin til anvendelse ifølge krav 1 eller 2, hvor cytokinet indgives ved lokal indgivelse, hvor den lokale indgivelse af cytokinet er ved mucosal indgivelse.
4. Cytokin til anvendelse ifølge krav 3, hvor den mycosale indgivelse vælges fra gruppen bestående af indgivelse via åndedrætskanalen, indgivelse via mavetarmkanalen, intravesikal indgivelse og intravaginal indgivelse.
5. Cytokin til anvendelse ifølge krav 4, hvor indgivelsen via åndedrætskanalen er nasal indgivelse.
6. Cytokin til anvendelse ifølge ethvert af kravene 3 til 5, hvor cytokinet indgives ved inhalation.
7. Cytokin til anvendelse ifølge ethvert af kravene 1 til 6, hvor cytokinet indgives med en dosis i området 0,1 MIE til 18 MIE pr. dag.
8. Cytokin til anvendelse ifølge ethvert af kravene 1 til 7, hvor cytokinet indgives som en daglig dosis, som er opdelt i to eller flere portioner pr. dag eller fra 1 til 10 portioner pr. dag.
9. Cytokin til anvendelse ifølge ethvert af kravene 1 til 8, hvor cytokinet indgives med en dosis til signifikant at forøge nitrogenoxid i den luft, som udåndes af patienten, for signifikant at forøge antallet af eosinofile granulocyter i det bronkoalveolære system, eller for signifikant at øge antallet af interleukin-2 receptorpositive celler i det bronkoalveolære system.
DK11705472.6T 2010-01-28 2011-01-27 Interleukin-2 eller interferon-alpha til anvendelse ved behandling af nikotin- eller spisehang DK2528617T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29913110P 2010-01-28 2010-01-28
EP10151979 2010-01-28
PCT/EP2011/051106 WO2011092231A1 (en) 2010-01-28 2011-01-27 Cytokines for the treatment of addictions

Publications (1)

Publication Number Publication Date
DK2528617T3 true DK2528617T3 (da) 2016-03-07

Family

ID=44318697

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11705472.6T DK2528617T3 (da) 2010-01-28 2011-01-27 Interleukin-2 eller interferon-alpha til anvendelse ved behandling af nikotin- eller spisehang

Country Status (7)

Country Link
US (1) US9028808B2 (da)
EP (1) EP2528617B1 (da)
DK (1) DK2528617T3 (da)
ES (1) ES2565486T3 (da)
PL (1) PL2528617T3 (da)
PT (1) PT2528617E (da)
WO (1) WO2011092231A1 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10244793B2 (en) 2005-07-19 2019-04-02 Juul Labs, Inc. Devices for vaporization of a substance
US10279934B2 (en) 2013-03-15 2019-05-07 Juul Labs, Inc. Fillable vaporizer cartridge and method of filling
EP3013355B1 (en) * 2013-06-25 2019-08-07 ICM - Institut du Cerveau et da la Moelle Epinière Il-2 for use in treating alzheimer disease and related disorders
US20160366947A1 (en) 2013-12-23 2016-12-22 James Monsees Vaporizer apparatus
MX2020012138A (es) 2013-12-23 2022-05-19 Juul Labs Inc Dispositivo, sistemas y metodos de vaporizacion.
USD842536S1 (en) 2016-07-28 2019-03-05 Juul Labs, Inc. Vaporizer cartridge
US10159282B2 (en) 2013-12-23 2018-12-25 Juul Labs, Inc. Cartridge for use with a vaporizer device
USD825102S1 (en) 2016-07-28 2018-08-07 Juul Labs, Inc. Vaporizer device with cartridge
US10076139B2 (en) 2013-12-23 2018-09-18 Juul Labs, Inc. Vaporizer apparatus
US10058129B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Vaporization device systems and methods
EP3226704B1 (en) 2014-12-05 2021-01-20 Juul Labs, Inc. Calibrated dose control
WO2016133890A1 (en) * 2015-02-19 2016-08-25 Srq Patent Holdings, Llc Compositions for e-cigarettes
BR112018016402B1 (pt) 2016-02-11 2023-12-19 Juul Labs, Inc Cartuchos de fixação segura para dispositivos vaporizadores
UA125687C2 (uk) 2016-02-11 2022-05-18 Джуул Лебз, Інк. Заповнювальний картридж випарного пристрою та способи його заповнення
US10405582B2 (en) 2016-03-10 2019-09-10 Pax Labs, Inc. Vaporization device with lip sensing
USD849996S1 (en) 2016-06-16 2019-05-28 Pax Labs, Inc. Vaporizer cartridge
USD848057S1 (en) 2016-06-23 2019-05-07 Pax Labs, Inc. Lid for a vaporizer
USD851830S1 (en) 2016-06-23 2019-06-18 Pax Labs, Inc. Combined vaporizer tamp and pick tool
USD836541S1 (en) 2016-06-23 2018-12-25 Pax Labs, Inc. Charging device
USD887632S1 (en) 2017-09-14 2020-06-16 Pax Labs, Inc. Vaporizer cartridge

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2463816A1 (fr) 1979-08-24 1981-02-27 Servimetal Cartouche pour filtration active et traitement des metaux et alliages liquides
US4992271A (en) 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
DE3621828A1 (de) 1986-06-28 1988-01-14 Biotest Pharma Gmbh Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff
ES2065434T3 (es) 1990-06-21 1995-02-16 Edith Dr Huland Utilizacion de aerosoles que contienen citocinas y aerosoles que contienen citocinas propiamente dichos.
US5780012A (en) 1990-06-21 1998-07-14 Huland; Edith Method for reducing lung afflictions by inhalation of cytokine solutions
ES2245780T3 (es) 1994-05-18 2006-01-16 Nektar Therapeutics Metodos y composiciones para la formulacion de interferones como un polvo seco.
DE19811016A1 (de) 1998-03-13 1999-09-16 Dade Behring Marburg Gmbh Gebrauchsfertiges Prothrombinzeitreagenz auf der Basis von rekombinantem Gewebsfaktor
US20080063625A1 (en) 2004-07-30 2008-03-13 Cel-Sci Corporation Method for Managing Cholesterol with a Serum-Free and Mitogen-Free Cytokine Mixture
RU2290947C1 (ru) 2005-10-27 2007-01-10 Александр Иванович Воронов Способ лечения опийной наркомании

Also Published As

Publication number Publication date
WO2011092231A1 (en) 2011-08-04
ES2565486T3 (es) 2016-04-05
US20130028861A1 (en) 2013-01-31
US9028808B2 (en) 2015-05-12
EP2528617B1 (en) 2016-01-06
PL2528617T3 (pl) 2016-09-30
PT2528617E (pt) 2016-03-31
EP2528617A1 (en) 2012-12-05

Similar Documents

Publication Publication Date Title
DK2528617T3 (da) Interleukin-2 eller interferon-alpha til anvendelse ved behandling af nikotin- eller spisehang
US6893654B2 (en) Two-stage transmucosal medicine delivery system for symptom relief
EP0748228B8 (en) powder FOR THE PROVOCATION OF AIR PASSAGE NARROWING AND/OR THE INDUCTION OF SPUTUM
JP2548056B2 (ja) Ｉ型糖尿病に係る自己免疫疾患の抑制および予防用製剤
EP0739206B1 (en) Composition for drug delivery comprising nicotine or a derivative thereof and starch microspheres and method for the manufacturing thereof
ES2539532T3 (es) Activación de respuestas inmunitarias innatas y adaptativas por parte de un extracto de ginseng
KR20200132852A (ko) 펩티드 yy 약학적 제형, 조성물, 및 방법
JP2002509074A (ja) 熱ショックタンパク質を使用する、炎症性疾患を処置する方法
RO121834B1 (ro) Dispozitiv pentru administrarea unui agent activ
EP1080717A1 (en) Method for dispensing antioxidant vitamins by inhalation
CN112135625A (zh) 一种预防或治疗covid-19新冠肺炎的药物、食物及其应用
JPWO2002055091A1 (ja) 抗アレルギー剤
WO2006049286A1 (ja) アレルギー性疾患予防・治療剤
JP2002526420A (ja) 脊椎動物における実質的に無毒で生物学的に活性な粘膜アジュバント
Bereda Bronchial asthma: etiology, pathophysiology, diagnosis and management
Pedersen Treatment of nocturnal asthma in children with a single dose of sustained‐release theophylline taken after supper
US20040166113A1 (en) Remedies for interstitial pneumonia, method of preparing animal model of said disease, and screening method using the same
Kumbhar et al. Novel route of inhaled insulin for diabetes treatment
Almér et al. Insulin inhalation with absorption enhancer at meal‐times results in almost normal postprandial insulin profiles
JP2002179588A (ja) チオレドキシンファミリーに属するポリペプチド類を含む炎症予防乃至治療剤
CN113521118A (zh) 一种雾化牡蛎人参复合肽及其制备方法与应用
US20100063251A1 (en) Compositions and methods for treatment of chronic fatigue syndrome and neurodegenerative diseases
CN115461356A (zh) 用于预防或治疗covid-19的肽
US20040115244A1 (en) Methods and compositions for nicotine replacement therapy
JP2005225853A (ja) アレルギー性疾患又は呼吸器系疾患の予防ないし治療剤